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OBJECTIVE—We evaluated insulin sensitivity and insulin se-
cretion across the entire range of fasting (FPG) and 2-h plasma
glucose (PG), and we investigated the differences in insulin
sensitivity and insulin release in different glucose tolerance
categories.
RESEARCH DESIGN AND METHODS—A total of 6,414 Finn-
ish men (aged 57  7 years, BMI 27.0  3.9 kg/m
2) from our
ongoing population-based METSIM (Metabolic Syndrome in
Men) study were included. Of these subjects, 2,168 had normal
glucose tolerance, 2,859 isolated impaired fasting glucose (IFG),
217 isolated impaired glucose tolerance (IGT), 701 a combination
of IFG and IGT, and 469 newly diagnosed type 2 diabetes.
RESULTS—The Matsuda index of insulin sensitivity decreased
substantially within the normal range of FPG (17%) and 2-h PG
(37%) and was approximately 65 and 53% in the diabetic
range of FPG and 2-h PG, respectively, compared with the
reference range (FPG and 2-h PG 5.0 mmol/l). Early-phase
insulin release declined by only approximately 5% within the
normal range of FPG and 2-h PG but decreased signiﬁcantly in
the diabetic range of FPG (by 32–70%) and 2-h PG (by 33–51%).
Changes in insulin sensitivity and insulin secretion in relation to
hyperglycemia were independent of obesity. The predominant
feature of isolated IGT was impaired peripheral insulin sensitiv-
ity. Isolated IFG was characterized by impaired early and total
insulin release.
CONCLUSIONS—Peripheral insulin sensitivity was already de-
creased substantially at low PG levels within the normoglycemic
range, whereas impairment in insulin secretion was observed
mainly in the diabetic range of FPG and 2-h PG. Obesity did not
affect changes in insulin sensitivity or insulin secretion in relation
to hyperglycemia. Diabetes 58:1212–1221, 2009
T
ype 2 diabetes is preceded by a long pre-diabetic
state, characterized by mild elevation of fasting
and/or postprandial glucose levels. This asymp-
tomatic phase may last for years, and about
one-third of these individuals ﬁnally develop type 2 diabe-
tes (1). The pre-diabetic state, deﬁned by an oral glucose
tolerance test (OGTT), includes impaired fasting glucose
(IFG), impaired glucose tolerance (IGT), or their combi-
nation (2). Epidemiological studies have shown that IFG
and IGT represent two distinct subgroups of abnormal
glucose tolerance (1,3–5) that differ in their age and sex
distribution (6,7) and associated cardiovascular risk (8).
Therefore, IFG and IGT are likely to have different
pathophysiologies.
Impaired insulin secretion and impaired insulin action
are the two main pathophysiological disturbances leading
to abnormal glucose tolerance. Previous studies on the
role of impaired insulin secretion and insulin resistance in
the development of IFG and IGT have yielded contradic-
tory results (4–23). Inconsistencies across the studies are
explained by differences in study populations, study de-
signs and methods to assess insulin resistance and insulin
secretion, and most importantly by a small sample size.
Categorization of glucose tolerance is based on arbitrary
cutoff points of glucose levels, and therefore different
subgroups cannot fully account for changes in -cell
function and insulin action with increasing glycemia. Only
a few studies have examined insulin secretion and/or
insulin sensitivity as a function of glucose concentrations
(13,24–28). These studies have been, however, relatively
small, and most of them were conducted in non-Caucasian
populations.
The aim of this study was to evaluate insulin sensitivity
and insulin secretion across the entire range of fasting and
2-h plasma glucose (PG) from normal glucose tolerance
(NGT) to type 2 diabetes to understand better the patho-
physiology of the pre-diabetic state. Furthermore, we
investigated the differences in insulin sensitivity and insu-
lin release in different glucose tolerance subgroups. To
address these questions, we collected a large sample of
carefully phenotyped middle-aged Finnish men.
RESEARCH DESIGN AND METHODS
A total of 6,414 men from the ongoing population-based cross-sectional
Metabolic Syndrome in Men (METSIM) study were included in the study.
Subjects, aged from 45 to 70 years, were randomly selected from the
population register of the town of Kuopio in eastern Finland (population
95,000). Every participant had a 1-day outpatient visit to the Clinical Research
Unit at the University of Kuopio, including an interview on the history of
previous diseases and current drug treatment and an evaluation of glucose
tolerance and cardiovascular risk factors. Fasting blood samples were drawn
after 12 h of fasting followed by an OGTT. The study was approved by the
ethics committee of the University of Kuopio and Kuopio University Hospital,
and it was in accordance with the Helsinki Declaration.
Clinical measurements. Height and weight were measured to the nearest 0.5
cm and 0.1 kg, respectively. BMI was calculated as weight (kg) divided by
height (m) squared. Waist (at the midpoint between the lateral iliac crest and
lowest rib) and hip circumference (at the level of the trochanter major) were
measured to the nearest 0.5 cm. Body composition was determined by
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1212 DIABETES, VOL. 58, MAY 2009bioelectrical impedance (RJL Systems) in subjects in the supine position after
a 12-h fast (29).
OGTT. A 2-h OGTT (75 g of glucose) was performed, and samples for PG and
insulin were drawn at 0, 30, and 120 min. Glucose tolerance was evaluated
based on OGTT as follows: NGT (fasting PG [FPG] 5.6 mmol/l and 2-h PG
7.8 mmol/l), isolated IFG (FPG 5.6–6.9 mmol/l and 2-h PG 7.8 mmol/l),
isolated IGT (FPG 5.6 mmol/l and 2-h PG between 7.8 and 11.0 mmol/l),
IFG  IGT (FPG 5.6–6.9 mmol/l and 2-h PG 7.8–11.0 mmol/l), and newly
diagnosed type 2 diabetic subjects (FPG 7.0 mmol/l and/or 2-h PG 11.1
mmol/l) (2).
Laboratory determinations. Plasma glucose was measured by enzymatic
hexokinase photometric assay (Konelab Systems reagents; Thermo Fischer
Scientiﬁc, Vantaa, Finland). Insulin was determined by immunoassay (ADVIA
Centaur Insulin IRI no. 02230141; Siemens Medical Solutions Diagnostics,
Tarrytown, NY).
Calculations. The trapezoidal method was used to calculate glucose area
under the curve (AUC) and insulin AUC during the OGTT. Surrogate indexes
of insulin sensitivity and insulin secretion were calculated according to
published formulas (Tables 1 and 2) (25,30–33), using glucose and insulin
concentrations at 0, 30, and 120 min.
Statistical analysis. Data are presented as the means  SD, median (25th,
75th percentile) for continuous variables, or as count (percentage) for
categorical variables. Variables with nonnormal skewed distribution were
logarithmically transformed before analysis. Continuous variables were com-
pared across the categories of glucose tolerance by ANOVA or after adjust-
ment for covariates using the general linear model. Pairwise comparisons
between the groups were performed by Bonferroni post hoc tests (with P
value adjustment for multiple testing for each variable). Categorical variables
were examined by 
2 test. Spearman’s rank correlation was used to compare
the surrogate indexes with the reference measures. Analyses were conducted
with SPSS version 14 (SPSS, Chicago, IL). P values 0.05 were considered
statistically signiﬁcant.
Validation study. A separate sample of 287 nondiabetic Finnish offspring of
type 2 diabetic patients from the region of Kuopio was used to validate the
OGTT-derived indexes of insulin secretion and insulin sensitivity against
parameters measured by the intravenous glucose tolerance test (IVGTT) and
euglycemic-hyperinsulinemic clamp. The study protocol has been described
previously (10). All subjects underwent a 2-h OGTT (75 g of glucose) and on
a separate occasion a frequently sampled IVGTT, followed by a euglycemic-
hyperinsulinemic clamp for 120 min, as described previously (10). The study
was approved by the ethics committee of the University of Kuopio and was in
accordance with the Helsinki Declaration.
Spearman’s correlations were calculated between insulin AUCs during the
ﬁrst 10 min and during 10–60 and 0–60 min of the IVGTT, considered as the
reference indexes of ﬁrst-phase, second-phase, and total insulin secretion,
respectively, and surrogate indexes of insulin secretion (Tables 1 and 2). The
ratio of total insulin AUC and total glucose AUC during 0–30 min of the OGTT
(InsAUC30/GluAUC30) displayed the highest correlation with the ﬁrst-phase
insulin release during the IVGTT (rho  0.67, P  0.001) (Table 1). Insulin
AUC during 120 min of the OGTT (InsAUC120), alone or adjusted for the
corresponding glucose AUC (InsAUC120/GluAUC120), showed the highest
correlation with the second-phase and total insulin release (rho ranging from
0.75 to 0.78, P  0.001) (Table 1). Spearman’s correlation analysis was also
performed between the ratio of whole-body glucose uptake to lean body mass
and to mean insulin concentration during the last 60 min of the euglycemic
clamp (MLBM/I), considered as a reference index of insulin sensitivity, and
surrogate indexes of insulin sensitivity. Matsuda ISI (calculated from glucose
and insulin levels at 0, 30, and 120 min of the OGTT) showed the highest
correlation with the clamp-derived MLBM/I (rho  0.78, P  0.001) (Table 2).
Based on the above correlation analyses, we used Matsuda ISI as a
surrogate index of insulin sensitivity, InsAUC30/GluAUC30 as a surrogate index
of the early-phase insulin release, and InsAUC120/GluAUC120 as a surrogate
index of total insulin release in the METSIM study. We also calculated two
disposition indexes as the products of insulin sensitivity  insulin secretion
(DI30  Matsuda ISI  InsAUC30/GluAUC30, DI120  Matsuda ISI  InsAUC120/
GluAUC120) as a measure of the -cell response to insulin sensitivity. In a
previous study analyzing several measures of disposition indexes based on
insulin secretion and insulin sensitivity from an OGTT, the product of
InsAUC/GluAUC and Matsuda ISI was the only combination that followed the
hyperbolic relationship that is the requirement for a disposition index (34). A
recent study indicated that oral disposition index (insulinogenic index 
1/HOMA-IR, where HOMA-IR is the homeostasis model assessment for insulin
resistance) is predictive of diabetes over 10 years (35). We used 1/HOMA-IR as
an approximate measure of insulin sensitivity in the liver (33,36). The
limitation of this index is that it also measures peripheral insulin sensitivity.
RESULTS
Baseline characteristics. The age of 6,414 men in this
study was 57  7 years, and their BMI was 27.0  3.9
kg/m
2. Altogether, 2,168 subjects (34%) had NGT, 2,859
(45%) had isolated IFG, 217 (3%) had isolated IGT, 701
(11%) had a combination of IFG and IGT, and 469 (7%) had
newly diagnosed type 2 diabetes. A total of 492 subjects
with previously diagnosed diabetes were excluded from
statistical analyses. As shown in Table 3, subjects with
NGT and isolated IFG were signiﬁcantly younger than
subjects with isolated IGT, IFG  IGT, and newly diag-
nosed type 2 diabetes. Subjects with isolated IGT were
signiﬁcantly more obese than subjects with isolated IFG
(according to waist-to-hip ratio and fat mass). Subjects
with IFG  IGT and newly diagnosed type 2 diabetes were
TABLE 1
Spearman correlation coefﬁcients between surrogate indexes of
-cell function and insulin release during the ﬁrst phase (0–10
min) and second phase (10–60 min) and total (0–60 min) during
an IVGTT
-Cell function indexes
Insulin release during an
IVGTT
First
phase
Second
phase Total
HOMA- 0.568 0.645 0.663
Insulinogenic index 0.579 0.469 0.541
InsAUC30/GluAUC30 0.666 0.707 0.743
	InsAUC120/	GluAUC120 0.375 0.409 0.405
InsAUC120/GluAUC120 0.648 0.750 0.775
First-phase Stumvoll 0.651 0.663 0.702
Second-phase Stumvoll 0.662 0.692 0.730
Fasting insulin 0.548 0.747 0.735
Insulin at 30 min of an OGTT 0.615 0.691 0.715
Insulin at 120 min of an
OGTT 0.429 0.673 0.645
Insulin AUC during an OGTT 0.558 0.770 0.776
P  0.001 for all correlation coefﬁcients. Indexes of -cell function
were calculated as described previously: HOMA-(30), insulinogenic
index(31),	InsAUC120/	GluAUC120(25),InsAUC120/GluAUC120(31),
ﬁrst phase Stumvoll (32), and second phase Stumvoll (32). InsAUC
30/
GluAUC30  (insulin at 0 min  insulin at 30 min of an OGTT)/
(glucose at 0 min  glucose at 30 min of an OGTT).
TABLE 2
Spearman correlation coefﬁcients between surrogate indexes of
insulinsensitivityandinsulinsensitivityassessedbyaeuglycemic-
hyperinsulinemic clamp (M value)
Insulin sensitivity
during clamp
M value MLBM/I
Insulin sensitivity indexes
1/fasting insulin 0.625 0.716
1/HOMA-IR 0.605 0.708
QUICKI* 0.605 0.708
Matsuda ISI* 0.699 0.776
MCR Stumvoll 0.701 0.683
ISI Stumvoll* 0.705 0.693
Indexes of insulin sensitivity were calculated as described previ-
ously: HOMA-IR (30), quantitative insulin sensitivity index (30),
Matsuda ISI (33), MCR Stumvoll (31), and ISI Stumvoll (31). For all
correlation coefﬁcients, P  0.001. *Surrogate indexes were vali-
dated against MLBM/I. ISI, insulin sensitivity index; MCR, metabolic
clearance rate; QUICKI, quantitative insulin sensitivity index.
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isolated IGT.
Insulin sensitivity according to fasting and 2-h PG
concentration. We generated different categories of FPG
and 2-h PG to investigate the relationship between the
peripheral insulin sensitivity (Matsuda ISI) or markers of
early-phase and total glucose-stimulated insulin secretion
and glycemia. Categories with FPG 5.0 mmol/l and 2-h PG
5.0 mmol/l were set as the reference categories. We ob-
served a considerable decrease in age- and BMI-adjusted
peripheral insulin sensitivity (17%) within the normal range
of FPG, compared with the reference category. Insulin sen-
sitivity further decreased to 50% within the range of IFG
and decreased to 67% in the diabetic range of FPG (Fig.
1A). A substantial decrease in insulin sensitivity (37%) was
also observed within the normal range of 2-h PG. Insulin
sensitivity further decreased to 51% within the IGT range
and to 57% within the diabetic range of 2-h PG (Fig. 1B).
When changes in insulin sensitivity according to the levels of
both FPG and 2-h PG were examined, the highest insulin
sensitivity was observed in subjects with FPG 5.0 mmol/l
and 2-h PG 5.0 mmol/l, and the lowest insulin sensitivity
was seen in subjects in the diabetic range of FPG and
2-h PG (supplementary Fig. 1, available in an online
appendix at http://diabetes.diabetesjournals.ord/cgi/
content/full/db08-1607/DCI).
Insulin release according to fasting and 2-h PG
concentration. Age- and BMI-adjusted early-phase insulin
release (InsAUC30/GluAUC30) decreased only slightly
(4%) within the normal range of FPG. It further de-
creased within the range of IFG and diabetes to 25 and
70%, respectively (Fig. 1C). The early-phase insulin re-
lease decreased by 6% within the normal range of 2-h PG,
and further decreased to 23 and 50% within the range
of IGT and diabetes, respectively (Fig. 1D). Age- and
BMI-adjusted total insulin release (InsAUC120/GluAUC120)
decreased to 13% within the range of IFG, and to 70%
within the diabetic range of FPG (Fig. 1E). Total insulin
release increased by 14% with higher 2-h PG up to 9.9
mmol/l, and then it decreased to 45% within the diabetic
range of 2-h PG (Fig. 1F). The largest decreases in both
early-phase (32 to 50%) and total (17 to 45%)
insulin release were observed within the range of FPG
from 7.0 to 7.9 mmol/l (Fig. 1C and E).
Disposition index. The early-phase DI30 and total DI120
decreased with higher FPG within the normal range by
21 and 18%, respectively. Within the IFG range, the
reduction in DI30 and DI120 reached 63 and 57% (Fig.
2A). As a function of 2-h PG, DI30 and DI120 decreased to
41 and 30% in the normal range and further decreased
to 60 and 48% in the IGT range (Fig. 2B).
Compensatory insulin secretion. Compensatory insulin
secretion was not observed, despite a signiﬁcant decrease
in insulin sensitivity within the normal range of FPG, but,
in contrast, the early-phase insulin release started to fall.
However, compensatory total insulin secretion already
started at low 2-h PG levels, and insulin release increased
up to 10 mmol/l and then started to decrease (supplemen-
tary Fig. 2). A decrease in DI indexes was already substan-
tial in the normal ranges of FPG and 2-h PG. Our ﬁndings
remained essentially similar after adjustment for glucose
level (analyses based on FPG were adjusted for 2-h PG,
and analyses based on 2-h PG were adjusted for FPG) in
addition to age and BMI.
Insulin sensitivity and insulin release according to
glucose levels in nonobese and obese individuals. No
signiﬁcant interaction between BMI and glucose levels in
determining insulin sensitivity was found. Obese subjects
(BMI 27 kg/m
2) within the reference categories of FPG
and 2-h PG (5.0 mmol/l) had reduced insulin sensitivity
by 45 and 41% compared with nonobese subjects (BMI
27 kg/m
2). The decrease in insulin sensitivity with higher
FPG and 2-h PG was similar in both nonobese and obese
subgroups: 17% (nonobese subjects) and 13% (obese
subjects) within the normal range of FPG and 37 and
36%, respectively, within the normal range of 2-h PG
(Fig. 3A and B). Obese subjects within the reference
categories of FPG and 2-h PG had increased early-phase
(70 and 54%) and total insulin release (68 and 46%)
compared with nonobese subjects. However, changes in
both early-phase and total insulin release with higher FPG
or 2-h PG were comparable in nonobese and obese sub-
jects (Fig. 3). The interaction between glucose levels and
BMI (cutoff point of 27 kg/m
2) in determining insulin
release was not signiﬁcant, except for the interaction
between 2-h PG and BMI in determining DI120 (P  0.001).
TABLE 3
Clinical and anthropometric characteristics of study participants according to glucose tolerance status
n NGT
Isolated
IFG Isolated IGT IFG  IGT
Newly
diagnosed
diabetes P Total
n — 2,168 2,859 217 701 469 — 6,414
Age (years) 6,414 57.5  6.7 56.9  6.8 60.3  6.9 59.2  6.8* 59.6  6.4*† 6  10
31 57.7  6.8
BMI (kg/m
2) 6,410 25.8  3.4 27.0  3.6 26.9  3.7‡ 28.9  4.4 29.7  4.9 8  10
131 27.0  3.9
Weight (kg) 6,411 79.8  11.7 83.9  12.7 82.4  13.4§‡ 88.7  14.8 91.0  15.6 3  10
93 83.5  13.3
Waist circumference (cm) 6,410 94.6  9.6 97.9  10.4 98.7  10.1‡ 103.5  11.5 105.7  12.0 2  10
140 98.0  10.9
Hip circumference (cm) 6,409 99.4  6.2 101.1  6.4 100.6  6.7§‡ 103.4  7.9 104.5  8.1* 3  10
73 101.1  6.8
Waist-to-hip ratio 6,409 0.95  0.06 0.97  0.06 0.98  0.06 1.00  0.06 1.01  0.07 1  10
119 0.97  0.06
Fat mass (%) 6,401 22.5  6.3 23.4  6.0 26.2  6.8 27.2  6.7* 27.7  6.1† 3  10
108 23.9  6.5
BMI 27 kg/m
2 (median) 6,410 669 (31) 1,276 (45) 110 (51) 452 (65) 324 (69) 1  10
84 2,831 (44)
Positive family history of
diabetes 6,412 889 (41) 1,340 (47) 104 (48) 348 (50) 254 (54) 5  10
8 2,935 (46)
Data are means  SD or n (%). P values for overall comparison between ﬁve categories of glucose tolerance are shown (ANOVA for
continuous variables, 
2 test for categorical variables). Bonferroni post hoc tests (continuous variables): all pairwise comparisons between
categories of glucose tolerance were signiﬁcant at P  0.05, except for those marked as follows: *P 
 0.05 vs. isolated IGT; †P 
 0.05 vs.
IFG  IGT; ‡P 
 0.05 vs. isolated IFG; §P 
 0.05 vs. NGT.
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glucose tolerance. Age- and BMI-adjusted peripheral
insulin sensitivity (Matsuda ISI) was signiﬁcantly de-
creased by 26% in isolated IFG, by 30% in isolated IGT,
by 42% in IFG  IGT, and by 46% in newly diagnosed
type 2 diabetes, compared with NGT (Fig. 4A). Matsuda ISI
was signiﬁcantly lower in individuals with isolated IGT
than in individuals with isolated IFG (P  0.0016). A
signiﬁcantly greater decrease in isolated IFG than in
isolated IGT (31 vs. 16%, P  0.0028) was found when
insulin sensitivity was assessed with 1/HOMA-IR.
1/HOMA-IR was reduced by 39% in the IFG  IGT group
and by 45% in newly diagnosed type 2 diabetic subjects
(Fig. 4B). Categories of glucose tolerance status differed
signiﬁcantly also with respect to other indexes of insulin
sensitivity (Table 4). Compared with NGT, the age- and
BMI-adjusted early-phase insulin release (InsAUC30/
GluAUC30) was signiﬁcantly decreased by 8% in isolated
IFG, not changed in isolated IGT, decreased by 16% in
IFG  IGT, and decreased by 43% in newly diagnosed
type 2 diabetes (Fig. 4C). The difference between isolated
IFG and isolated IGT was not statistically signiﬁcant (8
vs. 0%, P  1.0). The total insulin release (InsAUC120/
GluAUC120) was signiﬁcantly reduced in isolated IFG
(6%) and in newly diagnosed type 2 diabetes (29%),
whereas no signiﬁcant changes were observed in isolated
IGT or in IFG  IGT compared with NGT (Fig. 4D).
Individuals with isolated IFG had signiﬁcantly lower total
FIG. 1. Insulin sensitivity (Matsuda ISI) (A and B), early-phase insulin release (InsAUC30/GluAUC30)( C and D), and total insulin release during
the OGTT (InsAUC120/GluAUC120)( E and F) across the categories of FPG and 2-h PG. Bars display the value of insulin sensitivity or insulin
release relative to the reference category (FPG <5.0 mmol/l, 2-h PG <5.0 mmol/l). Calculations were based on geometric means, adjusted for age
and BMI with the general linear model. Cutoff values for different categories of FPG were (in mg/dl): 90.1 (5.0 mmol/l), 99.1 (5.5 mmol/l), 108.1
(6.0 mmol/l), 117.1 (6.5 mmol/l), 126.1 (7.0 mmol/l), 135.1 (7.5 mmol/l), 144.1 (8.0 mmol/l), 153.2 (8.5 mmol/l), and 162.2 (9.0 mmol/l). Cutoff
values for different categories of 2-h PG were (in mg/dl): 90.1 (5.0 mmol/l), 108.1 (6.0 mmol/l), 126.1 (7.0 mmol/l), 144.1 (8.0 mmol/l), 162.2 (9.0
mmol/l), 180.2 (10.0 mmol/l), 198.2 (11.0 mmol/l), 216.2 (12.0 mmol/l), and 234.2 (13.0 mmol/l).
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16%, P  0.001). The HOMA- index, indicating basal
insulin release, was signiﬁcantly reduced by 17% in
isolated IFG (P  1.2  10
26), whereas it was increased
by 33% in isolated IGT (P  1.3  10
15), compared with
NGT. All categories of glucose tolerance status differed
signiﬁcantly with respect to all other indexes of insulin
secretion examined, as shown in Table 4.
Disposition index. The early-phase DI30 was lower in
isolated IGT than in isolated IFG (36 vs. 29% compared
with NGT, P  0.0003). In the IFG  IGT group, DI30 was
decreased by 53%, and in newly diagnosed type 2 dia-
betic subjects by 68% (Fig. 4E). In contrast, the total
DI120 was decreased to the same extent in isolated IFG and
isolated IGT (both 27%). DI120 was reduced signiﬁcantly
in the IFG  IGT group by 44% and in newly diagnosed
type 2 diabetic subjects by 62% (Fig. 4F).
All statistical analyses were also performed using a
cutoff point of 6.1 mmol/l (110 mg/dl) for FPG. All results
were essentially similar (supplemental Tables 1 and 2,
supplemental Fig. 3).
DISCUSSION
Our study is the largest population-based study focusing
on the pathophysiology of pre-diabetes using validated
surrogate markers for insulin sensitivity and insulin re-
lease. This allowed us to perform a detailed analysis on the
changes in insulin sensitivity and insulin secretion from
normal glucose levels to the diabetic range of hyperglyce-
mia. We demonstrated that insulin sensitivity was already
decreased substantially (by 17 and 37%, respectively)
within the normal range of FPG and 2-h PG. Insulin
sensitivity further decreased through the IFG and IGT
range and reached a reduction of approximately 65 and
53% in the diabetic range of FPG and 2-h PG. In contrast,
early-phase insulin release declined only slightly within
the normal range of FPG and 2-h PG (by approximately
5%) and reached a substantial decrease in the diabetic
range of FPG (50–70%) and 2-h PG (35–50%). Compen-
satory insulin secretion was entirely missing when FPG
increased from the normal range to the IFG range, but
compensatory insulin secretion was observed within the
normal range of 2-h PG. We also showed that peripheral
insulin resistance is the predominant feature of isolated
IGT, whereas impairment in early and total insulin release
characterize isolated IFG.
The novel ﬁnding of our study was the observation that
peripheral insulin sensitivity was already decreased con-
siderably at relatively low glucose levels within the normal
range of FPG and 2-h PG. Other studies addressing the
same question have been considerably smaller in size. In a
study including 188 subjects, Ferrannini et al. (24) re-
ported a decrease in insulin sensitivity (measured by
clamp) with higher 2-h PG levels within the NGT group.
The increase in insulin resistance was associated with
higher BMI, suggesting that obesity is the main factor
responsible for the decrease in insulin sensitivity. We
found that insulin sensitivity decreased comparably in
both nonobese and obese individuals by 37 and 36%,
respectively, within the 2-h PG range from 5.0 to 7.9
mmol/l. Thus, our ﬁndings suggest that obesity does not
affect insulin sensitivity related to hyperglycemia. In an-
other study (n  148), Ahre ´n (27) reported decreased
insulin sensitivity (14%) measured by clamp in post-
menopausal normoglycemic women within the highest
quartile of FPG.
The mechanisms leading to a decrease in insulin sensi-
tivity within the normal range of FPG and 2-h PG remain
unclear. Although high glucose (20 mmol/l) and/or high
insulin levels decrease glucose uptake in human adipose
cells in vitro (37), it is not known whether this effect could
be observed at moderately increased glucose concentra-
tions in vivo. Furthermore, our results show that despite a
substantial decrease in peripheral insulin sensitivity
(37%), 2-h PG could be maintained within the normal
range by a compensatory increase in total insulin release.
The pattern of changes in early-phase insulin release
differed from that of insulin sensitivity. The decrease was
small in the normal range (approximately 5%), pro-
gressed within the IFG and IGT range, and was substantial
within the diabetic range (reaching 70% and 51% for
diabetic FPG and 2-h PG, respectively). The defect in early
insulin response manifested at lower glucose levels than
the defect in total insulin response. Previous studies
(13,25,26,28) have not assessed the effect of obesity on the
FIG. 2. Disposition indexes corresponding to early-phase (DI30  Matsuda ISI  InsAUC30/GluAUC30) and total insulin release (DI120  Matsuda
ISI  InsAUC120/GluAUC120) across the categories of FPG (A) and 2-h PG (B). Cutoff values for different categories of FPG and 2-h PG are as
explained in Fig. 1.
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1216 DIABETES, VOL. 58, MAY 2009relationship between glucose levels and insulin secretion.
We showed that both early-phase and total insulin release
were substantially higher in obese subjects than in non-
obese subjects within the normal range of FPG and 2-h PG
(by 50–70%), but there was no signiﬁcant interaction
between obesity and glucose levels in determining insulin
release. Therefore, obesity does not seem to have a
major impact on further changes in insulin release in
hyperglycemia. Accordingly, Camastra et al. (38) have
observed that the dynamic aspects of -cell response to
glucose were unaltered in the morbidly obese non-
diabetic subjects.
Previous studies have been inconsistent with respect to
differences in insulin sensitivity between isolated IFG and
isolated IGT. Decreased peripheral insulin sensitivity in sub-
jects with isolated IGT compared with subjects with isolated
IFG has been reported in some studies using the clamp
method or IVGTT (9,10,12,14), but also similar impairment in
insulin action has been found in both isolated IFG and
isolated IGT in Pima Indians (13) and obese Chinese subjects
FIG. 3. Insulin sensitivity (Matsuda ISI) (A and B), early-phase insulin release (InsAUC30/GluAUC30)( C and D), and total insulin release in an
OGTT (InsAUC120/GluAUC120)( E and F) across the categories of FPG and 2-h PG in nonobese (BMI <27 kg/m
2; Œ) and obese subjects (BMI >27
kg/m
2; f). Bars display insulin sensitivity or insulin release relative to the reference category (FPG <5.0 mmol/l, 2-h PG <5.0 mmol/l).
Calculations were based on geometric means, adjusted for age and BMI, with the general linear model (performed separately in subgroups of
nonobese and obese subjects). Cutoff values for different categories of FPG and 2-h PG are as explained in Fig. 1. Ref., reference.
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DIABETES, VOL. 58, MAY 2009 1217(16). In two studies, the decrease in insulin sensitivity in
isolated IGT compared with isolated IFG was related to
obesity (11,17). In our study, peripheral insulin sensitivity
was signiﬁcantly more reduced in isolated IGT than in
isolated IFG (30 vs. 26%, P  0.0016). The decrease in
insulin sensitivity was quite similar in nonobese and obese
subjects (27 and 31%) with isolated IGT, indicating that
the reduction in peripheral insulin sensitivity in isolated IGT
was not explained by obesity.
Conﬂicting ﬁndings have been published on 1/HOMA-IR
as an index of hepatic insulin sensitivity (11,12,14,18–23).
In our study, 1/HOMA-IR was more reduced in isolated
IFG than in isolated IGT (31 vs. 16%). However,
HOMA-IR also reﬂects peripheral insulin sensitivity, and
therefore reliable results on hepatic insulin sensitivity can
be obtained only by using the tracer technique (13,39).
We observed a small reduction in early-phase insulin
release in isolated IFG (8%) but not in isolated IGT,
‡
‡
FIG. 4. Insulin sensitivity (Matsuda ISI and 1/HOMA-IR) (A and B), early-phase insulin release (InsAUC30/GluAUC30)( C), total insulin release
(InsAUC120/GluAUC120)( D), disposition index for early insulin release (DI30  Matsuda ISI  InsAUC30/GluAUC30)( E), and disposition index
for total insulin release (DI120  Matsuda ISI  InsAUC120/GluAUC120)( F) in different categories of glucose tolerance. Bars show percentage of
each index relative to NGT (reference, 100%). Calculations were based on geometric means, adjusted for age and BMI (ANCOVA). All pairwise
comparisons were statistically signiﬁcant (P < 0.05, Bonferroni post hoc test) except for those marked: *P > 0.05 vs. NGT, †P > 0.05 vs. isolated
IFG, ‡P > 0.05 vs. isolated IGT. Ref., reference. IIFG, isolated IFG; IIGT, isolated IGT; NewDM, newly diagnosed diabetes.
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DIABETES, VOL. 58, MAY 2009 1219compared with NGT. Furthermore, isolated IFG and iso-
lated IGT differed signiﬁcantly in basal and total glucose-
stimulated insulin release. Basal and total insulin release
were reduced in isolated IFG by 17 and 6%, respec-
tively, but increased in isolated IGT by 33% and 16%
compared with NGT. These results suggest that individu-
als with isolated IFG have impairment in both basal and
glucose-stimulated (early and total) insulin release,
whereas individuals with isolated IGT have increased
basal and total insulin release. Some previous studies
using IVGTT or clamp to assess insulin secretion have
reported impaired insulin release in individuals with iso-
lated IFG (9,10,13,14,16), whereas others have found im-
paired insulin release in individuals with IGT (11,15).
Studies based on OGTT measurements have reported
impaired early-phase insulin secretion (insulinogenic in-
dex) in individuals with IGT only (21,23) or in both
individuals with IGT or IFG (12,18,22). Few studies have
found decreased basal insulin secretion in IFG (11,22).
The currently accepted paradigm is that type 2 diabetes
develops when the pancreas is unable to secrete more
insulin to compensate for insulin resistance. However, in
the nondiabetic range of glucose levels, compensatory
total insulin release was observed only for increasing 2-h
PG levels (Fig. 1F). In contrast, in the nondiabetic range of
FPG levels, this compensatory hyperinsulinemia was en-
tirely missing, and insulin release (early-phase and total)
(Fig. 1C and E) linearly decreased with increasing FPG
levels and was lowest in the diabetic range, indicating a
major defect in insulin secretion. This observation is
consistent with recent evidence from genetic studies
showing that the insulin secretion defect is very often the
primary cause for type 2 diabetes (40). The changes in
insulin sensitivity and insulin secretion in response to
higher glucose levels in our study suggest that there are
two major pathways for the development of type 2 diabe-
tes, one leading to diabetes via the elevation of FPG and
another via postprandial hyperglycemia or 2-h PG. Pro-
spective follow-up studies including subjects with isolated
IFG and isolated IGT are needed, however, to conﬁrm this
hypothesis.
The strengths of this study are large size, homogeneous
study population, and validation of the methods used as
surrogate markers for insulin sensitivity and secretion.
The limitation of the study is that only middle-aged Finnish
men were included in the study, and therefore we do not
know if the results are valid for women or for other ethnic
and racial groups. Previous studies have not reported sex
differences in insulin secretion, but in some studies
women were more insulin sensitive than men (41–43).
Because of the large size of our cohort, we could not use
the most accurate methods to evaluate insulin sensitivity
(clamp) and insulin secretion (IVGTT or hyperglycemic
clamp) or hepatic insulin sensitivity (tracer techniques).
However, we validated our OGTT-derived indexes of insu-
lin secretion and insulin sensitivity against the gold stan-
dard measures in an independent sample of Finnish
subjects. We did not measure 1-h glucose during the
OGTT, which has been shown to be a better predictor of
future risk of diabetes than FPG and 2-h PG levels in a
recent study (44).
In summary, we showed in a large cohort of Finnish men
that the impairment of peripheral insulin sensitivity
started at relatively low PG levels within the normoglyce-
mic range. In contrast, the impairment of insulin secretion
progressed substantially only in the diabetic range of
fasting and 2-h glucose levels. Peripheral insulin resistance
was a predominant feature of isolated IGT, whereas im-
paired insulin secretion characterized isolated IFG.
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